Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

August 12, 2028

Study Completion Date

August 12, 2028

Conditions
High Risk Prostate Cancer
Interventions
DRUG

Tb-PSMA-I&T (Tb-PSMA)

Terbium-161 produce beta emission with the addition of Auger electrons which have higher linear energy transfer and a very short range. By that it has the potential to improve local and distal (micro-metastatic disease) efficacy with a similar safety profile. It will be given to patients with high risk locally advanced prostate cancer prior to Radical prostatectomy

Trial Locations (1)

Unknown

RECRUITING

Beilinson Hospital, Petah Tikva

All Listed Sponsors
lead

Rabin Medical Center

OTHER

NCT07208240 - Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial. | Biotech Hunter | Biotech Hunter